MEF2C and acute lymphoblastic leukemia: As CC1007 is designed to inhibit class IIa HDACs by blocking their interaction with MEF2C, we postulate that CC1007 may interfere in the interaction between HDAC7 and MEF2 in pre-B-ALL cells.